1[1]Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer overview of the randomised trials[J].Lancet, 1996,348(9036): 1189.
2[2]Pritchard KI. GnRH analogues and ovarian ablation: their integration in the adjuvant strategy [J ]. Recent Results Cancer Res,1998,1522: 85.
3[3]Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women[J]. Lancet,1992,339(8784): 1.
4[4]Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer,current trials working party of the cancer research campaign breast cancer trials group [J]. J Natl Cancer Inst, 1996,88(24): 1834.
5[5]Boccardo F,Rubagotti A,Amoroso D,et al. Italian breast cancer adjuvant chemo-hormone therapy cooperative group trials,GROCTA trials[J]. Recent Results Cancer Res, 1998,1524:53.
6[6]Boccardo F, Rubagotti A, Perotta, er al. Ovarian ablation versus goserelin with or without tamoxifen in per-perimenopausal patient with advanced breast cancer: result of a multicentric Italy study[J]. Ann Oncol, 1994,5 (4): 337.
7[7]Ravdin PM. Overview of randomized trials of systemic adjuvant therapy[J]. Cancer Treat Res,2000,103:157.
8[8]Jonat W,Kaufmann M,Blamey RW,et al.A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer[J]. Eur J Cancer, 1995,31A(2): 137.
9[9]Baum M. Tamoxifen-the treatment of choice,why look for alternatives? [J ]. Br J Cancer, 1998,78 ( suppl 4): 1.
